Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Culture

10 Jun 2022

Elon Musk Tweets Psychedelics With Cybin CEO

Elon Musk has made waves again, talking about potential of psychedelics...

By Microdose NewsDesk

Finance

9 Jun 2022

Roth Capital Doubles Down on Cybin After DMT Acquisition

Roth Capital has reiterated its Buy rating and bullish price target for Cybin, a sign of faith in the company's programs considering the difficult market conditions....

By Microdose NewsDesk

Industry

7 Jun 2022

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Today we received news that Cybin is continuing to aggressively pursue its DMT development with the acquisition of a major DMT study from Entheon Biomedical...

By Microdose NewsDesk

Don’t Miss

6 Jun 2022

News You Might Have Missed: June 6th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

27 May 2022

Mydecine Closes Capital Raise

Today Mydecine announced the closing of a larger capital raise — they issued 2,447,130 shares at a price of $1....

By Microdose NewsDesk

Industry

26 May 2022

Ceruvia Lifesciences Working on Phase 2 Psilocybin Trial for OCD

Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase 2 clinical trial for the treatment of obsessive-compulsive disorder with psilocybin...

By Microdose NewsDesk

Industry

25 May 2022

Microdose Helps Bring Psychedelic Medicine to Davos

Microdose was there, to speak and be part of this leadership group bringing psychedelic medicine to a broader audience, one that could help move the industry forward....

By Microdose NewsDesk

Don’t Miss, Industry

24 May 2022

News You Might Have Missed: May 24th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

23 May 2022

COMPASS Presents Psilocybin Study to American Psychiatric Association

Positive data from phase IIb study shows potential of COMP360 psilocybin therapyin treatment-resistant depression...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.